Top Tech Companies (45)
Don't see your company?
Create a company profile
Norgine is a leading European specialist pharmaceutical company that has been bringing transformative medicines to patients for over a century. Our commitment to transforming people’s lives drives everything we do and our European experience, fully integrated infrastructure and exceptional partnership approach enables us to quickly apply creative solutions to bring life-changing medicines to patients that they may not otherwise be able to access. Norgine is proud to have helped 24 million patients around the world in 2021 and generated €505 million in net product sales, a growth of 10% over 2020. Norgine has a direct presence in 16 European countries, as well as Australia and New Zealand. We also have a strong global network of partnerships in non-Norgine markets. We are a flexible and fully integrated pharmaceutical business, with manufacturing (Hengoed, Wales and Dreux, France), third party supply networks and significant product development capabilities, in addition to our sales and marketing infrastructure. This enables us to acquire, develop and commercialise specialist and innovative products that make a real difference to the lives of patients around the world. In 2012, Norgine established Norgine Ventures, a complementary business which supports innovative healthcare companies through the provision of debt-like financing in Europe and the US. For more information, please visit www.norgineventures.com.
Acurable is a fast-growing, venture backed MedTech start-up with offices in London and Seville. We create accurate and user-friendly wearable medical devices intended to be used by patients at home. Our award-winning, patented technology enables for the first time the automated diagnosis and management of respiratory conditions. It is the product of more than 10 years’ research at Imperial College London by Acurable’s founder, Professor Esther Rodriguez Villegas, and has been recognised as a breakthrough in respiratory medicine, winning some of the most respected awards in the industry, among them an XPrize and several Innovate UK grants. It has also featured in national and international media, including earlier this year in the BBC Horizon documentary How to Sleep Well with Michael Mosley. In 2020 our first product, AcuPebble SA100, became the first medical device in the world to obtain the CE mark for the automated diagnosis of obstructive sleep apnoea at home, and a few months later the product gained FDA clearance for home sleep apnoea testing in the US. AcuPebble SA100 is now in use within healthcare organisations across the UK and Europe, and will be launching in the USA in the coming months. At the same time we continue our research to develop new products that will fundamentally improve the lives of millions of people suffering from serious chronic conditions such as COPD, Asthma and Epilepsy.
Pharmacierge is the digital e-prescribing service chosen by private clinicians to deliver medication to their patients throughout the UK and worldwide. Clinicians create and transfer e-prescriptions to our pharmacy near London's Harley Street, for free delivery to their patients*. GMC clinicians in private practice can register for our e-prescription platform here: www.pharmacierge.com/register. Alternatively call 0207 637 9755 or email us via www.pharmacierge.com/contact Key features of our service: - Free for clinicians and clinics - E-prescribe securely for patients within a few clicks - E-prescriptions do not require original hard copies sent by post - Save time coordinating with pharmacies - Patients receive a phone call and/or SMS requesting secure payment - Secure compatibility with all practice systems - Discreet packaging and tracked delivery - Competitively priced medication - Clinician reviews: www.pharmacierge.com/clinicians Pharmacierge is located next to the Royal Society of Medicine, at the heart of London's Harley Street Medical Area. We maintain the highest standards of patient care as expected by elite clinicians throughout the private pathway. *Free Tracked Delivery Nationwide
Pheon Therapeutics is leveraging two decades of ADC experience to build a novel pipeline of next generation ADCs which offer the potential to treat solid tumors and liquid cancers that do not respond to other treatments. Understanding there is no “one size fits all” in engineering ADCs, Pheon takes a methodical approach to ADC development. Using both novel and clinically validated monoclonal antibodies (mAbs) and arming them either with warheads from their proprietary payload platform which boasts a novel mechanism of action or with off-the-shelf linker payload combinations, Pheon is finely attuned to balancing safety and efficacy for each target. Pheon’s lead program exploits a novel target that is highly expressed in a broad range of solid tumors. The lead agent is expected to reach IND within the next 18 months. Backed by expert, specialist healthcare investors Atlas Venture, Brandon Capital, Forbion and Research Corporation Technologies, Pheon Therapeutics has a world class, proven leadership team that brings together the best of ADC engineering, clinical strategy and business expertise. The company has state-of-the-art medicinal chemistry laboratories in London (United Kingdom), and a commercial office in Boston (United States).
AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. We aim to address complex health issues and enhance people's lives through our core therapeutic areas: immunology, oncology, neuroscience, eye care, aesthetics and other areas of unmet need.
H.E.L Group’s mission is to work together with chemistry, safety and biotechnology experts to engineer and unleash the full potential of the scientific community. To this end, H.E.L develops and manufactures innovative scientific instruments and software designed to optimize the efficiency, safety and productivity of key processes in chemistry and biology applications. The H.E.L team of 70 includes highly skilled process and software engineers, based at their extensive research and manufacturing facilities in the UK, as well as sales and support offices around the world. H.E.L has a long history of solving complex challenges for customers. For more than 30 years the Company has worked with businesses and laboratories globally, providing proprietary automated solutions for the pharma, biotechnology, chemical, battery and petrochemical sectors. Following significant growth, and with annual revenues exceeding £10 million, the Company is extending the reach of its products to support and enable R&D and process optimization further across the US, China and India.
Accessible AI for all drug discovery researchers. At Ro5, we provide the benefits of AI and digital transformation through a software platform that empowers our clients to focus on what they’re best at - drug discovery. Ro5 makes AI accessible to the industry by providing the expertise, infrastructure, software, models, and data necessary for digital transformation. Our software products are developed for real-world challenges, solving the unique problems faced by our clients that focus on R&D. Our solutions augment researcher’s workflows, enable data-driven decisions, and accelerate research. Ro5 has 5 years of experience providing services and software for pharmaceutical companies and CROs in projects spanning the entire drug discovery and development pipeline. Ro5 has a growing portfolio of scientific publications with 3 papers and 13 awarded patents. Contact us to learn more about how Ro5’s platforms and digital transformation could help achieve your and your organization’s research goals.
We need to shift to a world where we treat the individual, not just the disease. Our inventions work in combination with medicine to deliver personalized, optimized dosing, to provide bespoke universal healthcare access and improve outcomes for patients with chronic diseases. Closed Loop Medicine is a TechBio company developing combination prescription drug + software products, with the aim of bringing forward the promise of precision care. Our proprietary technology platform facilitates personalized drug dose optimization through integration of medicines and software with patient-led digital experiences and closed loop models of care. To learn more about our mission to deliver #PrecisionCareForAll, please visit: www.closedloopmedicine.com
Helping independent pharmacies to transform into diagnostic centres.
For 45 years, we’ve been creating high-quality medicines and making them accessible to the people who need them. We are a trusted, reliable partner and dependable source of over 760* high-quality generic, speciality and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe. We have 32 manufacturing plants, 8 R&D centres and c8,800 employees worldwide. *As of February 2023 Subscribe to our channel on YouTube https://youtube.com/@hikmapharmaceuticals5668 For all product information and enquiries, please contact us at [email protected]
Dunad Therapeutics is a biopharmaceutical company focusing on the development of next-generation targeted oral protein degradation therapies. Dunad’s platform enables selective degradation via direct target modification using tunable mono-valent small molecules, allowing for the development of more drug-like, orally bioavailable and CNS-accessible protein degraders
Pear Bio is a computational biology company that uses organ-on-a-chip and computer vision technology to recreate, visualize and compute the human tumor microenvironment and its effects on cancer progression. We are building an atlas of cancer progression to help research hospitals/pharma test experimental drugs and to help clinicians evaluate potential treatment options for each patient to improve outcomes. Our technology is applicable across solid tumors and we are currently working on a pipeline of biomarker negative cancers, with triple negative breast cancer as the lead indication. Our team has experience in big pharma and R&D tools, and our medical advisory board includes oncologists from MD Anderson, Imperial College London, Stanford University Medical Center and UCSF.
Back in 2018, we realised there was a huge problem in the world of skincare: people don't just struggle with their skin – they struggle with how they're supposed to deal with it. With no truly effective solutions out there, low confidence levels and high frustrations make it difficult for us to bring our best selves to the day ahead. We knew there had to be a better way to give everyone's skin what it really needed. So, with a small (but growing) team of dermatologists, pharmacists, direct-to-consumer experts and other brilliantly innovative people, we decided to change the face of skincare. And so, here we are – on a mission to build an accessible way for people to tackle their skin goals once and for all, with powerful, personalised solutions that truly work. Start tackling your skin goals with our free online dermatology consultation and sign up with the code LINKEDIN23 to get your first Daily Doser for £4.99
To create a healthier future for patients with life-threatening diseases, we are using our pioneering human extracellular matrix (ECM)-based discovery platform to develop a portfolio of programmes in fibrosis and solid tumours. Using human in vitro models that better recreate the natural cell microenvironment is transforming our ability to identify new targets, determine mechanisms of action, and increase the success rate of therapeutic candidates. We have pioneered the world’s first human extracellular matrix-based discovery platform to aid in the discovery of targets and biomarkers as well as drug profiling. Using our technology, we have a unique ability to study tissue- and disease-specific human ECM scaffolds, and to model diseases to study mechanisms of action. Our improved understanding of the role of the ECM in human enables the identification of more relevant drug targets and biomarkers. For drug discovery, we incorporate human ECM into our in vitro models, thereby recreating the natural cell microenvironment so that drug candidates can be tested in the context they will ultimately be used in. With the potential to predict the efficacy of candidates more accurately at an earlier stage, the platform can reduce late-stage clinical failures and accelerate discovery.
At Lifebit, we're pushing forward the frontiers of health and knowledge by democratising access to omics data. We enable all researchers, whether novice or advanced, to run complex analyses and generate meaningful insights fast. Lifebit CloudOS is the world’s first federated genomics platform for unified and secure research over distributed big data - wherever data resides. From top tier pharmaceutical organisations to global research institutes to genetics companies and more, Lifebit CloudOS leads the way with our best-in-class UX/UI, seamless integration to open-source tools, marketplace of proprietary ones, powerful cohort browser, and advanced AI functionality. At Lifebit, we are open source pioneers, innovators redefining our industry. Our driving mission - to revolutionise bioinformatics and biomedical data analysis forever. We are growing fast and looking for more superstars to join our team.
Order, track and get reminders for your NHS prescriptions – all in one place. Plus, get your medicine delivered to your door for free
We are a biopharmaceutical company and wholly owned subsidiary of Alfasigma S.p.A. focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, including primary biliary cholangitis (PBC) and severe alcohol-associated hepatitis (sAH). In a new age of liver disease treatment, our team is developing vital therapies to meet the needs of those living with rare and serious liver disease. We are committed to improving patients’ lives and addressing the liver community’s most pressing needs. Our corporate headquarters is located in New Jersey. For more information about Intercept, please visit our website at: www.interceptpharma.com and follow us on X at: @InterceptPharma.
Grow Pharma is the leader in supplying unlicensed cannabis medicines in the UK. Grow Pharma was established by Grow Biotech and IPS Pharma, combining cannabis sector expertise with 18 years’ experience manufacturing and importing unlicensed medicines
JUNE Medical Group is a women-owned medical devices company with offices in the UK, USA and Sweden. The company supplies selected products from leading manufacturers, and develops its own medical instruments, including the Galaxy II self retaining retractor – an extraordinary tool featuring the world’s first ever light attachment, Galaxy II™ LUX Approved Supplier: Galaxy II is already on the system in NHS Supply Chain, The Mount Sinai Hospitals, U.S. Department of Veterans Affairs approved (DAPA number is SP0200-21-H-0057) Circle Health Group, Baylor Scott & White Health The Queens Award for Enterprise: INNOVATION 2021 Women Owned Certified JUNE Medical incl Mosaic Surgical Manufacturing Most Trusted Surgical Medical Device Company 2022 - UK Best New Business 2015 UK Entrepreneur of the Year 2017 Growth Champion by Dept Int Trade 2019 Champions of Trade BAB /US Embassy UK 2021 UK CEO of the Year 2021
We’re an innovative and forward-thinking Commercial Pharma analytics startup based in the UK. Since 2014 we’ve been focusing our efforts on providing cutting edge input to pharmaceutical organisations throughout Europe and North America. By combining years of experience in healthcare, pharmaceutical and data , we provide a powerful tool for acquiring real actionable insights to Commercial strategy, Formulary status, Salesforce effectiveness, targeting & segmentation, Sales analytics and many more.
